Ulinastatin protects brain against cerebral ischemia/reperfusion injury through inhibiting MMP-9 and alleviating loss of ZO-1 and occludin proteins in mice

Exp Neurol. 2018 Apr:302:68-74. doi: 10.1016/j.expneurol.2017.12.016. Epub 2017 Dec 30.

Abstract

Background: The effects of Ulinastatin (UTI) on the blood-brain barrier (BBB) in the acute phase of cerebral ischemia/reperfusion (I/R) are not clear. This study was to investigate the potential protective effects of UTI on the BBB and the underlying mechanisms.

Methods: Male CD-1 mice were subjected to transient middle cerebral artery occlusion (tMCAO) and randomly assigned to four groups: Sham (sham-operated), tMCAO (tMCAO+0.9% saline), UTI-L (tMCAO+UTI 1500U/100g) and UTI-H (tMCAO+UTI 3000U/100g) group. UTI was administered immediately after reperfusion in the UTI-L and UTI-H groups. At 24h after reperfusion, the neurological deficit, brain water content, and infarct volume were determined. Western blot and quantitative reverse transcription polymerase chain reaction (qRT-PCR) were used to examine the expression of matrix metalloproteinase (MMP)-9, Zonula occludens-1 (ZO-1) and occludin in ischemic cerebral cortex. The integrity of the BBB was assessed by the leakage of Evans blue.

Results: Compared with tMCAO group, both UTI-L and UTI-H groups showed significantly (P<0.001) ameliorated the neurological deficit (2.00±0.71 and 1.60±0.55 vs. 4.60±0.55), lessened brain water content (82.99%±0.21% and 82.05%±0.59% vs. 84.28%±0.0.57%) and decreased the infarct volume (38.52%±1.72% and 24.78%±1.20% vs. 49.48%±1.93%). In addition, significantly (P<0.001) decreased expression of MMP-9 (0.48±0.06 and 0.37±0.05 vs.0.76±0.10 for protein and 2.88±0.23 and 2.17±0.16 vs. 3.90±0.24 for mRNA) and alleviated loss of ZO-1 (0.19±0.04 and 0.24±0.05 vs. 0.25±0.03) and occludin (0.74±0.08 and 0.87±0.07 vs. 0.94±0.06) proteins were observed in both UTI-L and UTI-H groups.

Conclusion: UTI protects the brain against ischemic injury potentially via down-regulating the expression of MMP-9 and alleviating loss of ZO-1 and occludin proteins to restore the BBB permeability.

Keywords: Cerebral ischemia/reperfusion; Matrix metalloproteinase-9; Occludin; Ulinastatin; Zonula occludens-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Animals
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / pathology
  • Brain Edema / etiology
  • Brain Edema / prevention & control
  • Brain Infarction / etiology
  • Brain Infarction / prevention & control
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Gene Expression Regulation / drug effects
  • Glycoproteins / therapeutic use*
  • Ischemic Attack, Transient / complications
  • Ischemic Attack, Transient / drug therapy
  • Male
  • Matrix Metalloproteinase 9 / genetics
  • Matrix Metalloproteinase 9 / metabolism*
  • Mice
  • Nervous System Diseases / etiology
  • Nervous System Diseases / prevention & control*
  • Neurologic Examination
  • Neuroprotective Agents / therapeutic use*
  • Occludin / genetics
  • Occludin / metabolism*
  • RNA, Messenger
  • Trypsin Inhibitors / therapeutic use*
  • Zonula Occludens-1 Protein / genetics
  • Zonula Occludens-1 Protein / metabolism*

Substances

  • Glycoproteins
  • Neuroprotective Agents
  • Occludin
  • Ocln protein, mouse
  • RNA, Messenger
  • Tjp1 protein, mouse
  • Trypsin Inhibitors
  • Zonula Occludens-1 Protein
  • Matrix Metalloproteinase 9
  • urinastatin